File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Intravitreal ranibizumab for neovascular glaucoma: an interventional case series

TitleIntravitreal ranibizumab for neovascular glaucoma: an interventional case series
Authors
KeywordsAntibodies, monoclonal
Light coagulation
Glaucoma, neovascular
Retinal neovascularization
Vascular endothelial growth factor
Issue Date2011
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.cohk.org.hk/journals.php
Citation
Hong Kong Journal of Ophthalmology, 2011, v. 15 n. 1, p. 6-11 How to Cite?
AbstractObjective: To evaluate the efficacy of ranibizumab in treating neovascular glaucoma. Design: Prospective interventional case series. Participants: Six eyes of 6 patients. Method: Six eyes with refractory neovascular glaucoma were treated with one dose of 0.5 mg intravitreal ranibizumab followed by laser panretinal photocoagulation. Patients were divided into 2 groups based on angle status for comparison. Recurrence was defined as re-emergence of iris neovascularization, and an intraocular pressure of more than 21 mm Hg after stabilization. Results: The patients’ mean age was 59 years and the mean follow-up 23 weeks. Three eyes had open-angle glaucoma, and three had a closed-angle configuration glaucoma. In 5 (83%) of the eyes, neovascularization completely regressed within the first 48 hours of intravitreal ranibizumab injection. Overall mean intraocular pressure dropped from 27.0 mm Hg pretreatment to 18.3 mm Hg 1 week post–intravitreal ranibizumab. The mean anti-glaucoma drop usage decreased from 4.2 pre-treatment to 2.2 one month later. There was no recurrence throughout the initial 3 months, but 2 eyes with closed-angle configuration glaucoma recurred, with a mean time to recurrence of 14 weeks. Conclusions: These results suggested that intravitreal ranibizumab is a useful and safe adjunct in the management of neovascular glaucoma.
Persistent Identifierhttp://hdl.handle.net/10722/136335
ISSN

 

DC FieldValueLanguage
dc.contributor.authorWong, IYHen_US
dc.contributor.authorKoo, SCYen_US
dc.contributor.authorYuen, NSYen_US
dc.contributor.authorKo, Cen_US
dc.contributor.authorChan, CWNen_US
dc.date.accessioned2011-07-27T02:13:38Z-
dc.date.available2011-07-27T02:13:38Z-
dc.date.issued2011en_US
dc.identifier.citationHong Kong Journal of Ophthalmology, 2011, v. 15 n. 1, p. 6-11en_US
dc.identifier.issn1027-8230-
dc.identifier.urihttp://hdl.handle.net/10722/136335-
dc.description.abstractObjective: To evaluate the efficacy of ranibizumab in treating neovascular glaucoma. Design: Prospective interventional case series. Participants: Six eyes of 6 patients. Method: Six eyes with refractory neovascular glaucoma were treated with one dose of 0.5 mg intravitreal ranibizumab followed by laser panretinal photocoagulation. Patients were divided into 2 groups based on angle status for comparison. Recurrence was defined as re-emergence of iris neovascularization, and an intraocular pressure of more than 21 mm Hg after stabilization. Results: The patients’ mean age was 59 years and the mean follow-up 23 weeks. Three eyes had open-angle glaucoma, and three had a closed-angle configuration glaucoma. In 5 (83%) of the eyes, neovascularization completely regressed within the first 48 hours of intravitreal ranibizumab injection. Overall mean intraocular pressure dropped from 27.0 mm Hg pretreatment to 18.3 mm Hg 1 week post–intravitreal ranibizumab. The mean anti-glaucoma drop usage decreased from 4.2 pre-treatment to 2.2 one month later. There was no recurrence throughout the initial 3 months, but 2 eyes with closed-angle configuration glaucoma recurred, with a mean time to recurrence of 14 weeks. Conclusions: These results suggested that intravitreal ranibizumab is a useful and safe adjunct in the management of neovascular glaucoma.-
dc.languageengen_US
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.cohk.org.hk/journals.phpen_US
dc.relation.ispartofHong Kong Journal of Ophthalmologyen_US
dc.subjectAntibodies, monoclonal-
dc.subjectLight coagulation-
dc.subjectGlaucoma, neovascular-
dc.subjectRetinal neovascularization-
dc.subjectVascular endothelial growth factor-
dc.titleIntravitreal ranibizumab for neovascular glaucoma: an interventional case seriesen_US
dc.typeArticleen_US
dc.identifier.emailWong, IYH: wongyhi@hku.hk, ianyhwong@gmail.comen_US
dc.identifier.authorityWong, IYH=rp01467en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros186994en_US
dc.identifier.volume15en_US
dc.identifier.issue1-
dc.identifier.spage6en_US
dc.identifier.epage11en_US
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats